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New developments in the treatment of primary 
biliary cholangitis – role of obeticholic acid
Manan A Jhaveri
Kris v Kowdley
Liver Care Network, Swedish 
Medical Center, Seattle, wA, USA
Abstract: Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease 
that predominantly affects women in early to middle age. It is typically associated with autoan-
tibodies to mitochondrial antigens and results in immune-mediated destruction of small and 
medium-sized intrahepatic bile ducts leading to cholestasis, hepatic fibrosis and may prog-
ress to cirrhosis or hepatic failure and, in some cases, hepatocellular carcinoma. The clinical 
presentation and the natural history of PBC have improved over the years due to recognition 
of earlier widespread use of ursodeoxycholic acid (UDCA); about one-third of patients show 
suboptimal biochemical response to UDCA with poor prognosis. Until recently, UDCA was 
the only US Food and Drug Administration approved agent for this disease for more than 
two decades; obeticholic acid was approved in 2016 for treatment of patients with PBC with 
a suboptimal response or intolerance to UDCA. Currently, liver transplantation is the most 
effective treatment modality for PBC patients with end-stage liver disease. This review will 
focus on the recent advances in therapy of primary biliary cholangitis, with emphasis on 
obeticholic acid.
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Background
Primary biliary cholangitis (PBC) is a chronic, autoimmune, slowly progressive 
cholestatic liver disease that predominantly affects middle-aged women at a ratio 
of ~10:1 of women to men.1 Although the reason for this gender difference is not fully 
understood, X chromosome monosomy is observed in women with PBC, and it has 
been found that genes related to X-linked immunodeficiencies can lead to granuloma 
formation and elevated immunoglobulin (Ig) M levels, a frequent observation in PBC.2 
The worldwide prevalence rate of PBC is estimated to be between 67 and 940 cases 
per million population and the incidence is between 0.7 and 49 cases per million 
population per year.3 Human Development Index estimated that there is a positive 
association between the incidence of PBC and socioeconomic status; moreover, the 
incidence rate is low in developing countries.4 The prevalence rates of PBC are high 
in UK, Scandinavia, Canada and USA.4
The exact pathogenesis of PBC remains unclear. However, there is compelling 
evidence that the mechanism is likely related to a combination of genetic predisposition 
and environmental factors,3,5 explaining the geographic variation as well as familial 
occurrence of this disease. The immune-mediated destruction of bile duct epithelial 
cells drives the pathogenesis of PBC.6,7 Persistent destruction of the bile ducts leads 
to intrahepatic accumulation of cytotoxic bile acid, resulting in hepatocellular injury, 
fibrosis and cirrhosis.8
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The diagnosis of PBC is confirmed by the presence of at 
least two of the following three objective criteria: 1) biochem-
ical evidence of intrahepatic cholestasis based on elevated 
levels of alkaline phosphatase (ALKP) of $1.5 times the 
upper limit of normal (ULN) for .24 weeks; 2) the presence 
of serum titers of antimitochondrial antibodies (AMAs) of 
more than or equal to 1:40; and 3) liver histology compat-
ible with features of PBC, characterized by nonsuppurative 
cholangitis and granulomatous destruction of interlobular 
bile ducts with exclusion of drug-induced liver injury.8,9 The 
disease usually presents with a cholestatic pattern of liver 
test abnormalities (predominant elevation of serum ALKP, 
out of proportion to elevation of serum aminotransferases 
[alanine aminotransferase {ALT}, aspartate aminotransferase 
{AST}]), and the vast majority of patients also have a posi-
tive serum AMA. AMAs are highly sensitive and specific, 
usually present in 95% of patients and given 98% specificity, 
liver biopsy is rarely required for the diagnosis of PBC.10 
Liver biopsy is helpful in staging and if there is suspicion of 
overlap syndromes (ie, with autoimmune hepatitis [AIH]) or 
coexisting liver conditions (ie, nonalcoholic steatohepatitis, 
drug-induced liver injury).11
Autoimmune liver diseases consist of PBC, primary 
sclerosing cholangitis, AIH, and IgG4 sclerosing cholangitis. 
In addition, some patients present with features of other auto-
immune liver diseases and will be categorized into a separate 
class called “overlap syndromes”.12–15 According to Paris 
criteria,12,16,17 an AIH–PBC overlap syndrome is accepted 
when two or three criteria of PBC as well as AIH are fulfilled. 
For AIH, the criteria are:12 1) serum ALT level of $5 times 
the ULN; 2) portal or periportal lymphocytic inflammation; 
and 3) moderate to severe periportal lymphocytic piecemeal 
necrosis. For PBC, the criteria are: 1) ALKP .2 times the 
ULN or gamma-glutamyl transferase (GGT) .5 times 
the ULN; 2) AMA positivity; and 3) florid duct lesions or 
destructive cholangitis on histologic examinations. Kuiper 
et al18 conducted a study on 134 patients of PBC–AIH overlap 
syndrome. They found that the sensitivity and specificity of 
Paris criteria for diagnosing overlap syndrome are 92% and 
97%, respectively.
The associations between PBC and extrahepatic auto-
immune diseases have been well established.19,20 More than 
50% of patients with PBC have other autoimmune disease. 
The extrahepatic autoimmune diseases that have been 
associated with PBC are Sjogren’s syndrome, systemic 
lupus erythematosus, rheumatoid arthritis, Raynaud’s dis-
ease, CREST syndrome, inflammatory bowel diseases and 
insulin-dependent diabetes mellitus. Among these conditions, 
Sjogren’s syndrome and Raynaud’s disease are strongly 
associated with PBC.20,21
The main aim in the management of PBC is to reverse 
injury from bile duct inflammation, improve the symp-
toms, slow down the disease progression, improve liver 
biochemistries, and prevent the long-term consequences of 
chronic cholestasis, such as pruritus, fatigue, osteoporosis 
and fat-soluble vitamin deficiencies.22 Since the introduc-
tion of hydrophilic bile acids such as ursodeoxycholic acid 
(UDCA) and their widespread use, the clinical presentation 
and progression of natural disease history of PBC patients 
have improved significantly over the past two decades.23–25 
However, about one-third of PBC patients show suboptimal 
biochemical responses to UDCA and remain at risk for con-
tinued progression of disease to more advanced diseases, 
including cirrhosis.26–28
Ursodeoxycholic acid
UDCA was the only drug approved by the US Food and Drug 
Administration for the treatment of PBC until the approval 
of obeticholic acid (OCA) in 2016.29 Chronic cholestasis will 
result in intrahepatic and systemic accumulation of cytotoxic 
bile acids that will initially promote hepatocyte prolifera-
tion but eventually lead to hepatocellular injury, apoptosis, 
fibrosis and cirrhosis. UDCA has multiple mechanisms 
of action in cholestatic conditions including protection of 
cholangiocytes and periportal hepatocytes from the cytotoxic 
effects of hydrophobic bile acids, stimulation of hepatocel-
lular and ductular secretion of hydrophobic bile acids and 
hepatocyte protection against bile acid–induced apoptosis. 
UDCA also has additional anti-inflammatory and immuno-
modulatory effects.30
Administration of UDCA increases the bile acid saturation 
in bile, resulting in increased bile acid clearance from blood 
and reduced cholestatic symptoms, specifically pruritus. 
These effects of UDCA occur with the optimal dose of 
13–15 mg/kg/day, and it has been proposed to have choleretic 
and anti-inflammatory effects. It shows improvement in liver 
biochemistries, slows the histologic progression of the disease 
and also improves overall survival, at least in those treated in 
the early stages of the disease.31,32 ter Borg et al33 conducted 
a prospective cohort study of 297 PBC patients and showed 
that administration of UDCA in patients with early histologic 
changes significantly improved transplant-free survival 
(1 year =99.7%, 5 years =87% and 10 years =71%) than 
that predicted by the Mayo model. Poupon et al34 conducted 
a meta-analysis of French, Canadian and Mayo Clinical 
trials and demonstrated that time to liver transplantation was 
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significantly improved in patients with moderate to severe 
disease (serum bilirubin level of $1.4 mg/dL, stage 3 and 
4 histologic abnormalities).
PBC is a rare and slowly progressive disease, and there-
fore, in most cases, individual clinical trials lacked power to 
demonstrate clinically significant differences in outcomes. 
So, the rates of clinical outcomes in patients treated with 
UDCA are compared to predicted rates of outcomes based 
upon the natural history models applied to a similar popula-
tion, assuming that they had not been treated with UDCA.35 
A Markov model36 has been used to compare survival of 
UDCA-treated patients to historical controls using the Mayo 
natural history model for PBC. This model predicted a sig-
nificantly better liver transplant-free survival with UDCA as 
compared to the spontaneous survival rate predicted by Mayo 
model.36 The overall survival rates without liver transplan-
tation were 84% and 66% at 10 and 20 years, respectively. 
In early-stage patients, 6% and 22% were predicted to prog-
ress to liver transplantation or death after 10 and 20 years, 
respectively.37 On the other hand, the probability of death or 
liver transplantation was significantly increased in patients 
in late stages of the disease.
However, ~30%–40% of PBC patients show suboptimal 
biochemical responses to UDCA or are intolerant to UDCA 
and remain at risk for continued progression to advanced 
diseases including cirrhosis.26,27 The biochemical response to 
UDCA after 1 year of treatment is a strong predictor of long-
term clinical outcomes and, thus, is very helpful in identify-
ing the patient population in need for additional therapies.38 
Multiple studies have proposed various criteria for improve-
ment in liver biochemistries as predictors of treatment success 
with UDCA.39,40 Large cohorts from France and UK showed 
that reduction of ALKP to ,1.5 times the ULN and a normal 
total bilirubin after 1 year of treatment with UDCA (Paris II 
criteria) are associated with excellent long-term survival and 
identified patients at low risk for disease progression.40 The 
collaboration of multiple international cohorts of .4,500 
PBC patients established the PBC GLOBE score which 
examined the risk of liver transplantation or death as a 
function of serum ALKP and total bilirubin after 1 year of 
UDCA treatment.39 The PBC GLOBE score incorporates age 
at the time of initiating UDCA therapy, serum ALKP, total 
bilirubin, albumin and platelet counts. A recent meta-analysis 
evaluated the impact of ALKP and total bilirubin levels on 
the long-term outcomes, such as liver transplantation and 
death.41 The authors concluded that the 10-year survival 
rate without a liver transplant after 1 year of treatment with 
UDCA was 84% in patients with ALKP level of #2 times 
the ULN and 86% in patients with bilirubin levels #1 times 
the ULN, as compared to 62% in patients with ALKP level 
of .2 times the ULN (P,0.0001) and 41% in patients with 
bilirubin levels .1 times the ULN (P,0.0001).41
Obeticholic acid
OCA (6α-ethyl-chenodeoxycholic acid) is a selective 
farnesoid-X-receptor (FXR) agonist derived from the pri-
mary human bile acid chenodeoxycholic acid that has been 
modified chemically to make it 100 times more potent than 
chenodeoxycholic acid.42,43 The FXR nuclear receptor is 
expressed in the liver, intestine, adrenal glands and kidneys; 
this nuclear receptor has a significant role in the synthesis 
and enterohepatic circulation of the bile acids. FXR activa-
tion in the liver reduces the conversion of cholesterol to bile 
acids by downregulating cytochrome P450 7A1 (CYP7A1) 
and CYP8B1, the primary enzymes involved in the synthe-
sis of bile acids, and increases the expression of bilirubin 
exporter pumps. In the ileum, activation of FXR receptor 
inhibits the uptake of bile acids by down regulating the 
sodium-dependent bile acid transporter and also decreased 
the production of bile acids by increasing the expression 
of fibroblast growth factor in the liver through inhibition 
of CYP7A1.42,44,45 Therefore, OCA increases bile flow in 
cholestatic conditions, and thereby protects the hepatocytes 
from accumulation of cytotoxic bile acids. In addition, 
various preclinical studies have found that OCA also has 
antifibrotic and anti-inflammatory properties.45 OCA has 
shown improvement in the biochemical markers of liver 
function in multiple clinical trials.46–48
Clinical trials
Two major Phase II studies46,47 and a Phase III study48 have 
evaluated the safety and efficacy of OCA in patients with 
PBC. The summary of OCA clinical trials is presented 
in Table 1.
The efficacy of OCA as monotherapy, comparing 10 
and 50 mg OCA, was evaluated in a Phase II, international, 
double-blind, placebo-controlled trial in patients with PBC 
with persistent elevation of ALKP (.1.5–2 times the ULN) 
and who had not been taking UDCA for at least 6 months.47 
The authors reported significant improvement in ALKP levels 
with both doses of OCA (the 10 mg OCA group showed the 
greatest decrease in ALKP, from 3.9× ULN to 1.9× ULN) as 
compared to placebo. The OCA group also showed signifi-
cant reduction in the values of GGT, conjugated bilirubin, 
C-reactive protein, IgM and tumor necrosis factor-α. Pruritus 
was the only main clinical adverse event in the OCA group 





as compared to placebo, and was more severe among patients 
with higher doses.47
Hirschfield et al46 published a randomized, double-blind, 
placebo-controlled trial evaluating the safety and efficacy 
of three doses of OCA (10, 25 and 50 mg/day) compared 
against placebo and UDCA. The study included patients 
with persistent elevation of ALKP of .1.5 times the ULN 
on a stable dose of UDCA for at least 6 months. The primary 
endpoint of significant reduction in serum ALKP from base-
line was met in all three OCA dose groups vs placebo. The 
mean relative change in ALKP from baseline was a decrease 
of 24%, 25% and 21% for the 10, 25, and 50 mg OCA groups, 
respectively, compared with a 3% decrease in the placebo 
group. The secondary endpoints including significant reduc-
tions in the values of GGT, ALT and AST were also met 
across all OCA treatment groups as compared to placebo. 
Moreover, OCA groups showed significant improvements 
in the inflammatory markers, such as C-reactive protein and 
IgM values.46
The authors also performed an open-label extension of 
the double-blind trial to evaluate the long-term safety and 
efficacy of OCA in patients with PBC.49 A total of 78 patients 
were enrolled and 61 patients completed the first year. The 
subjects were started on a 10 mg daily dose of OCA and 
titrated every 8 weeks to a maximum dose of 50 mg. The 
mean final daily dose of OCA at 12 months was 20 mg. 
The mean ALKP levels were decreased by 71 U/L (19%) at 
the 10 mg OCA dose, with a further decrease of 23 U/L (9%) 
after titrating the OCA dose from 10 to 25 mg. However, the 
mean ALKP increased by 8 U/L with titration from the 25 to 
50 mg dose. The major side effect was dose-related pruritus, 
which was reported in 87% of patients.49
The results from the only Phase III clinical trial of OCA,48 
the PBC OCA International Study of Efficacy (POISE), 
were the basis for the US Food and Drug Administration’s 
approval of OCA in the treatment of PBC patients with 
incomplete response to UDCA. POISE is an international, 
multicenter, randomized, double-blind, placebo-controlled, 
Phase III clinical trial that studied the safety and efficacy 
of OCA in PBC patients with an incomplete response to, or 
who are unable to, tolerate UDCA.48 An inadequate response 
to UDCA was defined as ALKP of $1.67 times the ULN 
and/or total bilirubin of more than the ULN but ,2 times 
the ULN. Most of the participants had been on UDCA for 
at least 12 months and were on a stable dose for at least 
3 months prior to enrollment. The primary endpoint was a 
composite of ALKP level of ,1.67 times the ULN, with a 
reduction of at least 15% from baseline, and a normal total 
bilirubin level after 12 months of therapy. Two hundred 
and seventeen subjects were randomized to receive either 
placebo, 10 or 5 mg of OCA titrated to 10 mg of OCA on 
the basis of the side effects and biochemical response at 
6 months. If patients had side effects such as severe pru-
ritus or had already met the composite primary endpoint, 
their dose was not increased. The median UDCA dose was 
15.5 mg/kg/day and 7% of patients were UDCA intolerant. 
The composite primary endpoint was met in an intention-
to-treat analysis with rates of 10% in the placebo group 
compared to 47% in the 10 mg OCA group and 46% in the 
dose-titrated 5–10 mg OCA group (P,0.0001 for both inter-
vention groups vs placebo). The mean decrease in ALKP 
from baseline was 39% in 10 mg OCA dose group, 33% 
in 5–10 mg titrated dose OCA group vs 5% in the placebo 
group (P,0.0001 for both intervention groups vs placebo). 
Table 1 Summary of major clinical trials of obeticholic acid in primary biliary cholangitis
Authors Inclusion criteria Use of 
UDCA
Duration Primary endpoints Number 
of subjects
OCA dose Primary 
endpoints met
Kowdley et al47 ALKP .1.5× the ULN, 
No UDCA .6 months























Nevens et al48 ALKP $1.67× the ULN 
and/or TB more than 
the ULN to 2× the ULN
Yes 12 months Serum ALKP of ,1.67× the 
ULN (with .15% reduction 












Abbreviations: ALKP, alkaline phosphatase; OCA, obeticholic acid; TB, total bilirubin; UDCA, ursodeoxycholic acid; ULN, upper limit of normal.
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In addition to the improvement in the serum level of ALKP, 
patients treated with 5 and 5–10 mg titrated dose had a 
greater decrease in total bilirubin compared to placebo 
(−0.02 and −0.05, respectively, vs 0.12; P-value for both 
OCA dose groups was ,0.001 vs placebo). Moreover, both 
the OCA intervention groups met predefined secondary 
endpoints including significant improvement of serum 
AST, serum ALT, serum GGT and the markers of inflam-
mation (P-value for both OCA dose groups was ,0.0005 
vs placebo).48
Ninety-seven percent of the patients who completed 
the double-blind phase of the POISE trial entered an open-
label extension phase, which is ongoing and will continue 
for a total of 5 years. The subjects who received OCA in 
the double-blind trial showed sustained improvements in 
ALKP levels; the placebo patients initiating treatment with 
OCA showed similar improvements in ALKP and bilirubin 
level as compared to the OCA-treated groups in the double-
blind phase.48
Safety and tolerability
Side effects related to OCA were usually mild to moderate 
and mostly related to pruritus. Treatment with OCA has been 
associated with increase in low-density lipoprotein-cholesterol 
and decrease in high-density lipoprotein-cholesterol 
(HDL-C) and triglycerides. The clinical significance of 
HDL-C reduction in PBC patients is unclear, as the patients 
had relatively high levels of HDL-C at baseline. Also, the 
absolute differences are relatively small. Other commonly 
reported adverse outcomes were fatigue, headache, and 
gastrointestinal side effects.46–48
Pruritus
Pruritus is the most common adverse effect in the interven-
tion group requiring change in dose and/or discontinuation 
of the treatment. The current evidence suggests that there 
is increased frequency and severity of pruritus, especially 
in OCA treatment groups at higher doses. Assessment of 
pruritus as a side effect in PBC is confounded by the fact that 
it is a common symptom in PBC patients. In the randomized 
clinical trial conducted by Hirschfield et al,46 the incidence 
of pruritus was 50% in the placebo group as compared to 
85% in the 25 mg OCA group (P,0.0003), 80% in the 
50 mg OCA group (P,0.006) and 47% in the 10 mg OCA 
group (P=0.7949). Sixteen percent of patients in the 10 mg, 
24% in the 25 mg and 37% in the 50 mg groups discontinued 
the trial due to severe pruritus, as compared to 0% in the 
placebo group. Overall, 10% of the OCA-treated patients 
discontinued the trial due to pruritus. The similar effects of 
OCA related to pruritus were also observed in the POISE 
trial.48 The incidence rates of pruritus were 38%, 56% and 
68% in the placebo, 5–10 and 10 mg groups, respectively. The 
severity of pruritus was less in the titration group (,1% dis-
continued the trial due to pruritus) as compared to the 10 mg 
OCA group (10% discontinued the trial due to pruritus). 
Overall, fewer than 6% of OCA-treated patients discontinued 
the trial due to pruritus. In the open-label extension phase 
with up to 2 years of follow-up, new incidence of pruritus 
is 15% in the 5–10 mg group and 21% in the 10 mg group, 
which is lower than the double-blind phase.50,51 In summary, 
pruritus is the major side effect of OCA in PBC, although 
this symptom can be managed in most patients by the use 
of bile acid sequestrants, antihistamines, dose reduction or 
symptomatic treatment.52
Dyslipidemia
PBC patients with early disease have elevated total cho-
lesterol likely due to high HDL-C levels. Changes in 
serum cholesterol levels were observed in clinical trials of 
OCA.46–48 Hirschfield et al46 reported changes in the serum 
lipid level, especially decrease in HDL and total cholesterol 
was observed in the OCA group. A dose-related decrease 
in total cholesterol of 3%, 5% and 13% was observed in 
the OCA 10, 25 and 50 mg groups, respectively, which was 
due to a decrease in HDL levels. There was a decrease in 
HDL level in all intervention groups; the mean reduction 
in HDL was 8 mg/dL (12%) in the 10 mg OCA group and 
9 mg/dL (13%) in both the 25 and 50 mg OCA groups, as 
compared to the placebo group that had relatively no change 
in HDL. The HDL levels were increased in all intervention 
groups during the off-treatment phase, which is suggestive 
of the OCA-induced effect on HDL. The POISE trial48 also 
observed similar effects of OCA on HDL level. It found 
reduction of 16% in the titrated group, 26% in the 10 mg 
group and 3% in the placebo group. Additionally, a modest 
decrease in triglycerides with no change in low-density 
lipoprotein-cholesterol was observed in the OCA-treated 
groups. This could be explained by the fact that the elimi-
nation of cholesterol is reduced by attenuating hepatic bile 
acid synthesis.53 The changes in cholesterol levels are sum-
marized in Table 2.
Other adverse events
Other common side effects that were observed in the treat-
ment groups were headache, rash, and gastrointestinal symp-
toms such as abdominal discomfort, nausea and vomiting.






The requirement for additional treatment for PBC is clearly 
recognized. Multiple noncontrolled studies found significant 
improvement in serum ALKP following administration of 
fibrates in PBC patients. However, these studies are limited 
due to lack of appropriate controls, smaller follow-up and 
ill-defined patient population. A Phase III randomized trial 
is currently underway. Novel immunologic treatments such 
as anti-interleukin-12, anti-CD80, anti-CD20 (rituximab), 
mesenchymal stem cells and cytotoxic T-lymphocyte 
antigen 4 (abatacept) are currently under investigation for 
the treatment of PBC.54–57
Summary
The recent approval of OCA in the treatment of PBC is an 
important advance for patients who are at an increased risk 
of liver-related complications despite UDCA therapy or 
are unable to tolerate UDCA. However, additional data are 
awaited to examine the effects of OCA in long-term clinical 
outcomes such as quality of life measures, decompensation 
of liver disease or liver-related mortality. The major adverse 
events related to OCA in PBC are dose-related side effects 
and possible negative effects on lipid profiles, although the 
clinical significance of this problem in cholestatic liver dis-
ease is unknown. A long-term study is underway to determine 
whether liver-related outcomes are improved with prolonged 
OCA treatment. Meanwhile, it is appropriate for clinicians 
to screen their patients with PBC and evaluate whether their 
ALKP is 1.67 times the ULN despite UDCA therapy, or in 
patients intolerant of UDCA to determine whether they are 
appropriate candidates for treatment with OCA.
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